Home › ECC - More Setback Leave PI3Ks In Immuno-Oncology's Shadow
 

Keywords :   


ECC - More Setback Leave PI3Ks In Immuno-Oncology's Shadow

2015-09-27 17:27:14| Biotech - Topix.net

Roche must be wondering how its cross-town rival Novartis has managed to show so much progress in the otherwise disappointing PI3K inhibitor class of cancer projects. Its earliest candidate in this class, pictilisib, has stumbled badly in a breast cancer trial at a time when Novartis is preparing to file buparlisib in the same disease.

Tags: leave shadow ecc setback

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.06Tnemec Elevates Coatings Education with Newly Appointed AMPP CIP Instructor
18.06Joanna Gaines, KILZ Debut Magnolia Lakehouse Collection
18.06Advanced Polymer Coatings Launches TriFLEX for Rail Cars
18.06Constantia Flexibles and ExxonMobil launch recyclable freezer film
18.06Hybrid Software unveils PACKZ 10
18.06KENT launches Nexgen Advanced swine products
18.06Swine NRC committee extends ingredient composition data request
18.06Ohio pork producers' donation to provide nutrient-rich protein for months of meals
More »